Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435409 · ClinicalTrials.gov registry record · Phase 3
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT00435409 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 442 participants.
The verdict
NCT00435409, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.
Interventions
- DRUG Capecitabine
- DRUG Sunitinib + Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435409
The ClinicalTrials.gov registry entry for NCT00435409 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00435409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435409 about?
NCT00435409 is a clinical study titled "A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer". The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.
What is the current status of trial NCT00435409?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2007-02. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00435409?
The interventions under investigation include: Capecitabine (DRUG), Sunitinib + Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00435409?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.